Clinical Trials

Title   [527707-13] A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Description   The purpose of this study is to determine whether DCVAC/PCa added onto Standard of Care Chemotherapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer.
IRB Number   14-182
Treatment   Oncology - Prostate Cancer
Status   Active
Principal Name   David Clarkson, M.D.
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us